All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – Twenty-three pharma companies are joining forces in the AMR Action Fund and have raised $1 billion in new money for the clinical development of antibiotic drugs.
LONDON – Twenty-three pharma companies are joining forces in the AMR Action Fund and have raised $1 billion in new money for the clinical development of antibiotic drugs addressing the most resistant bacteria. Working with philanthropic backers, the fund aims to bring two to four new antibiotics through to approval by 2030.
Targeted therapy offers an opportunity for personalized medicine that's specific for a patient's tumor, but the hyper-focused treatment creates possibilities for cells to mutate and become resistant to the therapy.
